ABL Bio
As of the edition of 20 October 2026, ABL Bio runs 5 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Status not established | 2 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Asciminib | Ends 2040 (patent) | 0 |
A route B row is one company at one target.